We served as healthcare regulatory counsel to Oak HC/FT, a venture capital firm investing in early to growth stage tech-enabled companies, in its $75 million Series C investment in Truepill. Truepill currently owns and operates six pharmacies across the U.S. The funds will be used to launch an at-home lab testing network – a new service that will further expand Truepill’s ecosystem of direct-to-patient capabilities, which includes Truepill Health telehealth network, pharmacy fulfillment, a custom-built EMR, and more.
Oak HC/FT Invests in Truepill
You Also May Be Interested In:
Representation of Parthenon Capital, a growth-oriented private equity firm, as healthcare regulatory counsel in its investment in RxSense, a high-growth healthcare technology company that utilizes its proprietary technology platform to provide innovative prescription savings solutions to consumers and pharmacy benefits administration and analytics to enterprise customers
Representation of Lead Capital Partners, a multi-family sponsored private equity firm, in its acquisition of Ladd Dental Group, Inc., a dental service provider with six locations throughout central Indiana
Lead Counsel to POINT Biopharma Inc. in its Proposed SPAC Business Combination with Research Alliance Corp. I
Lead Counsel to POINT Biopharma Inc. in connection with its proposed SPAC business combination with Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a special purpose acquisition company, sponsored by RA Capital Management. Upon closing, the combined company will be named POINT Biopharma Global Inc. and is expected to be listed on Nasdaq under the ticker symbol “PNT”.